@ARTICLE{
author={Cho BC,...,Secen Nevena M,...,(broj koautora 19)},
year={2021},
title={Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC},
journal={ANNALS OF ONCOLOGY},
volume={32},
number={},
pages={S1428-S1428},
document_type={Meeting Abstract},
}